Half-year report · HY
4574.TEDINET S100YVYD
Period2026-01-01 → 2026-06-30
Filed2026-08-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.6bn | 2026-01-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥6.4bn | 2025-01-01 → 2025-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Operating income | ¥17m | 2026-01-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | ¥46m | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | ¥41m | 2026-01-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥482m | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20m | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥40m | 2026-01-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥382m | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥44m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥923m | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥44m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥11.1bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥12.3bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥11.7bn | at 2025-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.7bn | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥3.8bn | at 2025-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.4bn | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥8.5bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2025-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.7bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.3bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.7bn | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2024-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥66m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥814m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥61m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥685m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥142m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥295m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥853m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥684m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥0.89 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥169.51 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.57 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 76.0% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.4% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2026-01-01 → 2026-06-30 | ¥2m |
| Otherother segments | revenue external | 2026-01-01 → 2026-06-30 | ¥2m |
| Otherother segments | segment profit | 2026-01-01 → 2026-06-30 | −¥14m |
| Reconciling Itemsreconciling | segment profit | 2026-01-01 → 2026-06-30 | −¥433m |
| Infection Control Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥111m |
| Infection Control Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥111m |
| Infection Control Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥92m |
| Pharmaceuticals Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥2.5bn |
| Pharmaceuticals Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥2.5bn |
| Pharmaceuticals Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥557m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2026-01-01 → 2026-06-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2026-01-01 → 2026-06-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2026-01-01 → 2026-06-30 | ¥450m |
| Otherother segments | revenue | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | segment profit | 2025-01-01 → 2025-06-30 | −¥7m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥396m |
| Infection Control Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥203m |
| Infection Control Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥203m |
| Infection Control Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥151m |
| Pharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| Pharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| Pharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥601m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | ¥443m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 499
| Item | Context | Value | Unit |
|---|---|---|---|
| Impairment loss ope cf | Prior1InterimDuration | 0 | JPY |
| Impairment loss ope cf | InterimDuration | － | JPY |
| Loss gain on sales of investment securities ope cf | Prior1InterimDuration | -347000000 | JPY |
| Loss gain on sales of investment securities ope cf | InterimDuration | － | JPY |
| Compensation income ope cf | Prior1InterimDuration | -14000000 | JPY |
| Compensation income ope cf | InterimDuration | － | JPY |
| Increase decrease in refund liabilities ope cf | Prior1InterimDuration | -2000000 | JPY |
| Increase decrease in refund liabilities ope cf | InterimDuration | -8000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1InterimDuration | -125000000 | JPY |
| Increase decrease in provision for bonuses ope cf | InterimDuration | -132000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1InterimDuration | 14000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | InterimDuration | 14000000 | JPY |
| Increase decrease in provision for loss on subleases ope cf | Prior1InterimDuration | -5000000 | JPY |
| Increase decrease in provision for loss on subleases ope cf | InterimDuration | -5000000 | JPY |
| Increase decrease in provision for transfer and removal expenses ope cf | Prior1InterimDuration | -19000000 | JPY |
| Increase decrease in provision for transfer and removal expenses ope cf | InterimDuration | － | JPY |
| Interest and dividends income ope cf | Prior1InterimDuration | -7000000 | JPY |
| Interest and dividends income ope cf | InterimDuration | -13000000 | JPY |
| Subsidy income2 ope cf | Prior1InterimDuration | -3000000 | JPY |
| Subsidy income2 ope cf | InterimDuration | -1000000 | JPY |
| Insurance income ope cf | Prior1InterimDuration | -1000000 | JPY |
| Insurance income ope cf | InterimDuration | － | JPY |
| Interest expenses ope cf | Prior1InterimDuration | 3000000 | JPY |
| Interest expenses ope cf | InterimDuration | 1000000 | JPY |
| Foreign exchange losses gains ope cf | Prior1InterimDuration | 0 | JPY |
| Foreign exchange losses gains ope cf | InterimDuration | -0 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1InterimDuration | 665000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | InterimDuration | 534000000 | JPY |
| Decrease increase in inventories ope cf | Prior1InterimDuration | -299000000 | JPY |
| Decrease increase in inventories ope cf | InterimDuration | -286000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1InterimDuration | 52000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | InterimDuration | 41000000 | JPY |
| Increase decrease in accrued expenses ope cf | Prior1InterimDuration | -122000000 | JPY |
| Increase decrease in accrued expenses ope cf | InterimDuration | -120000000 | JPY |
| Increase decrease in accounts payable other ope cf | Prior1InterimDuration | -319000000 | JPY |
| Increase decrease in accounts payable other ope cf | InterimDuration | -296000000 | JPY |
| Decrease increase in consumption taxes receivable payable ope cf | Prior1InterimDuration | 23000000 | JPY |
| Decrease increase in consumption taxes receivable payable ope cf | InterimDuration | -85000000 | JPY |
| Other net ope cf | Prior1InterimDuration | 56000000 | JPY |
| Other net ope cf | InterimDuration | 106000000 | JPY |
| Subtotal ope cf | Prior1InterimDuration | 55000000 | JPY |
| Subtotal ope cf | InterimDuration | -61000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1InterimDuration | 8000000 | JPY |
| Interest and dividends income received ope cf inv cf | InterimDuration | 14000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1InterimDuration | -3000000 | JPY |
| Interest expenses paid ope cf fin cf | InterimDuration | -1000000 | JPY |
| Proceeds from compensation ope cf | Prior1InterimDuration | 14000000 | JPY |
| Proceeds from compensation ope cf | InterimDuration | － | JPY |
| Proceeds from subsidy income2 ope cf | Prior1InterimDuration | 3000000 | JPY |
| Proceeds from subsidy income2 ope cf | InterimDuration | 1000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |